New Indication for Cancer-Fighting Drug

Atezolizumab (Tecentriq) is now approved for treating patients with BRAF V600 mutation-positive unresectable or metastatic melanoma in combination with cobimetinib and vemurafenib.
Source: AJN - Category: Nursing Tags: Drug Watch Source Type: research